Journal article
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
Abstract
BACKGROUND: For the prevention of attacks of hereditary angioedema (HAE), the efficacy and safety of subcutaneous human C1-esterase inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) was established in the 16-week Clinical Study for Optimal Management of Preventing Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy (COMPACT).
OBJECTIVE: To assess the long-term safety, occurrence of angioedema attacks, and use of rescue …
Authors
Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W
Journal
The Journal of Allergy and Clinical Immunology In Practice, Vol. 7, No. 6, pp. 1793–1802.e2
Publisher
Elsevier
Publication Date
7 2019
DOI
10.1016/j.jaip.2019.01.054
ISSN
2213-2198